CD8A and lymphoma: reported that the transfer of CD8+ T-cell-depleted DLI graft into cyclophosphamide-treated A20 leukemia/lymphoma-bearing mice increased the survival directly through a GvH anti-tumorreaction of donor CD4+ T-cells and indirectly through stimulation of recipient CD8+ T-cell antitumor immunity [81].